DWTX Quote, Financials, Valuation and Earnings

Bicara Therapeutics, Inc. has a net margin of -- compared to Dogwood Therapeutics, Inc.'s net margin of --. Dogwood Therapeutics, Inc.'s return on equity of -121.03% beat Bicara Therapeutics, Inc.'s return on equity of -26.44%.

Dogwood Therapeutics, Inc. has a consensus price target of $18.33, signalling upside risk potential of 205.05%. On the other hand Bicara Therapeutics, Inc. has an analysts' consensus of $32.57 which suggests that it could grow by 78.96%. Given that Dogwood Therapeutics, Inc. has higher upside potential than Bicara Therapeutics, Inc., analysts believe Dogwood Therapeutics, Inc. is more attractive than Bicara Therapeutics, Inc..

Dogwood Therapeutics, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Bicara Therapeutics, Inc. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Dogwood Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Bicara Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Dogwood Therapeutics, Inc. pays -- of its earnings as a dividend. Bicara Therapeutics, Inc. pays out -- of its earnings as a dividend.

Dogwood Therapeutics, Inc. quarterly revenues are --, which are smaller than Bicara Therapeutics, Inc. quarterly revenues of --. Dogwood Therapeutics, Inc.'s net income of -$15.7M is higher than Bicara Therapeutics, Inc.'s net income of -$36.3M. Notably, Dogwood Therapeutics, Inc.'s price-to-earnings ratio is -- while Bicara Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Dogwood Therapeutics, Inc. is -- versus -- for Bicara Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

CEL-SCI Corp. has a net margin of -- compared to Dogwood Therapeutics, Inc.'s net margin of --. Dogwood Therapeutics, Inc.'s return on equity of -121.03% beat CEL-SCI Corp.'s return on equity of -266.61%.

Dogwood Therapeutics, Inc. has a consensus price target of $18.33, signalling upside risk potential of 205.05%. On the other hand CEL-SCI Corp. has an analysts' consensus of $42.50 which suggests that it could grow by 558.92%. Given that CEL-SCI Corp. has higher upside potential than Dogwood Therapeutics, Inc., analysts believe CEL-SCI Corp. is more attractive than Dogwood Therapeutics, Inc..

Dogwood Therapeutics, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison CEL-SCI Corp. has a beta of 0.487, suggesting its less volatile than the S&P 500 by 51.259%.

Dogwood Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. CEL-SCI Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Dogwood Therapeutics, Inc. pays -- of its earnings as a dividend. CEL-SCI Corp. pays out -- of its earnings as a dividend.

Dogwood Therapeutics, Inc. quarterly revenues are --, which are smaller than CEL-SCI Corp. quarterly revenues of --. Dogwood Therapeutics, Inc.'s net income of -$15.7M is lower than CEL-SCI Corp.'s net income of -$5.7M. Notably, Dogwood Therapeutics, Inc.'s price-to-earnings ratio is -- while CEL-SCI Corp.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Dogwood Therapeutics, Inc. is -- versus -- for CEL-SCI Corp.. Usually stocks with elevated PS ratios are considered overvalued.

IGC Pharma, Inc. has a net margin of -- compared to Dogwood Therapeutics, Inc.'s net margin of -953.4%. Dogwood Therapeutics, Inc.'s return on equity of -121.03% beat IGC Pharma, Inc.'s return on equity of -94.42%.

Dogwood Therapeutics, Inc. has a consensus price target of $18.33, signalling upside risk potential of 205.05%. On the other hand IGC Pharma, Inc. has an analysts' consensus of $3.75 which suggests that it could grow by 1158.81%. Given that IGC Pharma, Inc. has higher upside potential than Dogwood Therapeutics, Inc., analysts believe IGC Pharma, Inc. is more attractive than Dogwood Therapeutics, Inc..

Dogwood Therapeutics, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison IGC Pharma, Inc. has a beta of 0.242, suggesting its less volatile than the S&P 500 by 75.839%.

Dogwood Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. IGC Pharma, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Dogwood Therapeutics, Inc. pays -- of its earnings as a dividend. IGC Pharma, Inc. pays out -- of its earnings as a dividend.

Dogwood Therapeutics, Inc. quarterly revenues are --, which are smaller than IGC Pharma, Inc. quarterly revenues of $191K. Dogwood Therapeutics, Inc.'s net income of -$15.7M is lower than IGC Pharma, Inc.'s net income of -$1.8M. Notably, Dogwood Therapeutics, Inc.'s price-to-earnings ratio is -- while IGC Pharma, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Dogwood Therapeutics, Inc. is -- versus 22.36x for IGC Pharma, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

NovaBay Pharmaceuticals, Inc. has a net margin of -- compared to Dogwood Therapeutics, Inc.'s net margin of -255.85%. Dogwood Therapeutics, Inc.'s return on equity of -121.03% beat NovaBay Pharmaceuticals, Inc.'s return on equity of -306.03%.

Dogwood Therapeutics, Inc. has a consensus price target of $18.33, signalling upside risk potential of 205.05%. On the other hand NovaBay Pharmaceuticals, Inc. has an analysts' consensus of $0.85 which suggests that it could fall by -29.75%. Given that Dogwood Therapeutics, Inc. has higher upside potential than NovaBay Pharmaceuticals, Inc., analysts believe Dogwood Therapeutics, Inc. is more attractive than NovaBay Pharmaceuticals, Inc..

Dogwood Therapeutics, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison NovaBay Pharmaceuticals, Inc. has a beta of 0.569, suggesting its less volatile than the S&P 500 by 43.103%.

Dogwood Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.80 per share. Dogwood Therapeutics, Inc. pays -- of its earnings as a dividend. NovaBay Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

Dogwood Therapeutics, Inc. quarterly revenues are --, which are smaller than NovaBay Pharmaceuticals, Inc. quarterly revenues of $521K. Dogwood Therapeutics, Inc.'s net income of -$15.7M is lower than NovaBay Pharmaceuticals, Inc.'s net income of -$1.3M. Notably, Dogwood Therapeutics, Inc.'s price-to-earnings ratio is -- while NovaBay Pharmaceuticals, Inc.'s PE ratio is 2.03x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Dogwood Therapeutics, Inc. is -- versus 2.35x for NovaBay Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.